Making Light Of Enzymes That Methylate DNA | Chemical & Engineering News
Latest News
Web Date: May 13, 2011

Making Light Of Enzymes That Methylate DNA

Epigenetics: A novel assay couples methyltransferase activity to bioluminescence
Department: Science & Technology
News Channels: JACS In C&EN
Keywords: epigenetics, DNA methylation, cancer, bioluminescence, inhibitors

Inside a cell's nucleus, methyl groups act like switches: When added to DNA, they turn off gene expression. In some cancer cells, clusters of these methylated bases silence tumor suppressor genes. As a result, some scientists think that inhibitors of enzymes that methylate DNA could treat cancer.

Now researchers report a sensitive one-pot assay to measure these enzymes' activity (Anal. Chem., DOI: 10.1021/ac200816m). They say that the assay could spur development of novel DNA methylation inhibitors.

To study these enzymes, called DNA methyltransferases (DNMTs), biochemists typically add radioactive methyl groups to DNA. The radioactive methyl group comes from tritiated S-adenosyl-L-methionine (AdoMet). Though sensitive, monitoring the addition of radioactive methyl groups has two shortcomings: It requires dealing with radioactivity, and it isn't amenable to high-throughput screens, because of a cumbersome DNA purification step.

To circumvent those problems, Vern Schramm of the Albert Einstein College of Medicine of Yeshiva University, and colleagues developed a bioluminescent method using nonradioactive AdoMet. The DNA methyltransferase converts AdoMet to S-adenosyl-L-homocysteine (AdoHcy). Schramm's method uses three enzymes to convert AdoHcy into adenosine triphosphate (ATP), which the enzyme luciferase then uses to power the production of a luminescent molecule. Luciferase produces a continuous signal with light intensity proportional to the activity of the methyltransferase, and the method measures that intensity. (It builds on 2010 work by Schramm's former postdoc Minkui Luo, now at Memorial Sloan-Kettering Cancer Center, who developed a similar assay to monitor protein methyltransferases.)

Schramm's team tested their assay by measuring the kinetic properties of representative bacterial and human DNA methylation enzymes. When compared to enzyme reaction rates measured by the radioactive method, the luciferase assay produced similar results. But unlike the radioactive assay, the researchers could monitor enzyme activity continuously, rather than having to take samples at distinct time points. They also found the assay could monitor the reactions of very slow, weakly active methylation enzymes.

The scientists then tested two molecules that they thought might inhibit DNMT, but found they had no effect on the enzyme. Schramm plans to use his assay to screen for novel compounds that could lead to anticancer drugs.

Yinsheng Wang of the University of California, Riverside, who developed a DNA methyltransferase assay based on liquid chromatography and mass spectrometry, praises the method's potential to screen possible inhibitors. He also points out the new method's convenience: Many biochemistry labs already have instruments to monitor bioluminescence. Yet Wang notes that the assay's reliance on multiple enzymes means that researchers will have to carefully screen any drug candidates to ensure they actually inhibit the DNMT and not an accessory enzyme.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment